This study in Phichit province, Thailand, aims to find and support adults born before 1992 who are at high risk for hepatitis B infection. Many people in this group were born before the universal hepatitis B vaccine was available and may not know they are infected. The study will invite nearly 240,000 eligible adults for free hepatitis B screening. Those who test positive will be linked to care at one of 12 district hospitals. Doctors will use simplified 2024 World Health Organization (WHO) guidelines to decide who needs treatment. Eligible individuals will receive a safe, effective daily medicine (tenofovir alafenamide). The study will use community health volunteers and phone reminders to help patients stay in care and take their medication regularly. Over three years, the study will track improvements in liver health and virus levels, aiming to prevent liver cirrhosis and cancer.

Start Date01 Jan 2026

Sponsor / Collaborator

The Task Force for Global Health, Inc.

NCT05652478

/ RecruitingPhase 2IIT

A Phase 2 Randomized Cross-Over Design Study of the Early Metabolic Effects of Dolutegravir or Tenofovir Alafenamide in Healthy Volunteers

Background:
People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes.
Objective:
To see how a common INSTI, dolutegravir (DTG), affects how the body uses energy. DTG will be compared with a non-INSTI drug, tenofovir alafenamide (TAF).
Eligibility:
Healthy people aged 18 to 55.
Design:
Participants will be screened. They will have a physical exam and blood tests. They will have a nutritional assessment and tests of their heart function.
Participants will have 2 inpatient stays at the clinic. Each stay will be for 11 nights, with a 3-week break between.
Both DTG and TAF are gel caps swallowed once per day by mouth. Participants will take 1 drug for 8 days during each stay.
Participants will have tests to see how their body uses energy:
They will spend 23 continuous hours in a special room that measures how much oxygen they breathe in and how much carbon dioxide they breathe out. They will do this a total of 6 times.
They will have a DEXA (dual-energy X-ray absorptiometry). DEXA is a kind of X-ray that measures body fat and bone density.
They will lie on a table. Electrodes will be placed on their hands and feet to measure body fat and lean body mass.
They will stand still on a platform for about 30 seconds. High-resolution laser cameras will scan their bodies.

Start Date11 Dec 2025

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT07253220

/ Not yet recruitingNot ApplicableIIT

Prospective, Randomized, Controlled Clinical Study Comparing TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma

Study Objective: To compare the efficacy and prognosis of systemic cancer therapy between TAF monotherapy and ETV plus TAF combination therapy in patients with unresectable, advanced hepatitis-B-related hepatocellular carcinoma (HBV-HCC).
Study Design: Prospective, interventional cohort study. Participants: Patients with histologically or radiologically confirmed unresectable, advanced HBV-HCC who are scheduled to receive immune-based systemic therapy at The Third Affiliated Hospital of Sun Yat-sen University. Detailed inclusion/exclusion criteria are provided below.
Intervention: Enrolled participants will be assigned to receive either TAF monotherapy or ETV combined with TAF for HBV suppression.
Primary Outcome: Overall survival (OS) at 24 months after initiation of systemic therapy, compared between the two HBV-treatment strategies.
Secondary Outcomes: Decline in HBV DNA and HBsAg levels at 1, 3, 12 and 24 months.
Sample Size: 120 HCC patients (60 per arm). Statistical Analysis: All analyses will be performed with SPSS. Continuous variables will be tested for normality (Shapiro-Wilk). Normally distributed data are presented as mean ± SD; non-normally distributed data as median (IQR). Twenty-four-month OS will be estimated by Kaplan-Meier curves and compared with a Cox proportional-hazards model adjusted for age, BCLC stage, AFP level, and ICI regimen. PFS will be compared using the log-rank test; ORR and HBV DNA undetectable rate will be compared with χ² tests. Inverse-probability-of-treatment weighting (IPTW) will address selection bias, and multiple imputation will handle missing data.

Start Date01 Dec 2025

Sponsor / Collaborator

Sun Yat-Sen University

100 Clinical Results associated with Tenofovir Alafenamide Fumarate

100 Translational Medicine associated with Tenofovir Alafenamide Fumarate

100 Patents (Medical) associated with Tenofovir Alafenamide Fumarate

1,841

Literatures (Medical) associated with Tenofovir Alafenamide Fumarate

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Treatment persistence among treatment-experienced people with HIV switching to integrase strand transfer inhibitor–based antiretroviral regimens

Article

Author: Chen, Megan ; de Boer, Melanie ; Trom, Cassidy ; Chuo, Ching-Yi ; Christoph, Mary J. ; Zachry, Woodie

AIMS:

Low rates of persistence are associated with poor outcomes in people with HIV (PWH). This retrospective cohort study assessed treatment persistence as measured by time to treatment switch in treatment-experienced (TE) PWH initiating integrase strand transfer inhibitor (INSTI)-based regimens.

METHODS:

United States prescription claims and medical history data from the IQVIA Longitudinal Access and Adjudication Dataset between January 1, 2018, and August 31, 2023, were analyzed. TE PWH with ≥1 prescription claim for initiation of an INSTI-based antiretroviral regimen during the index period (January 1, 2020, to December 31, 2022) were included. Descriptive analyses of demographic and comorbidity variables were performed, stratified by regimen. Kaplan-Meier analysis was used to evaluate time to subsequent treatment switch in the overall population and among PWH aged ≥50 years, those receiving Medicare, and those with mental health conditions or substance use disorders.

RESULTS:

Overall, 29,348 TE PWH were included. The majority of INSTI-based regimen initiations were for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (61%; n = 17,917), followed by dolutegravir/lamivudine (27.4%; n = 8034) and cabotegravir + rilpivirine (7.4%; n = 2186). A subsequent switch occurred in 3341 (11.4%) PWH. Risk factors for switch included female sex, Medicare/Medicaid coverage, and higher Charlson Comorbidity Index scores. B/F/TAF was associated with the fewest subsequent switches (9.2%; n = 1656) and was significantly less likely than any other regimen to lead to a subsequent switch, either in the overall population or in the three at-risk subgroups.

LIMITATIONS:

No data are available to determine the underlying reasons for initial treatment choice or subsequent treatment switch.

CONCLUSIONS:

This study provides evidence for greater treatment persistence with B/F/TAF versus other INSTI-based regimens. Unlike prior studies that focused on treatment-naïve individuals, this analysis uniquely evaluates persistence among treatment-experienced PWH initiating newer INSTI-based regimens.

31 Dec 2025·HIV Research & Clinical Practice

A peculiar case of persistent CPK elevation in a person diagnosed with acute HIV: what is behind?

Article

Author: Cattelan, Annamaria ; Pegoraro, Elena ; Nalesso, Federico ; Dal Bello, Luca ; Marinello, Serena ; Calandrino, Lucrezia ; Mazzitelli, Maria ; Ferrari, Anna

INTRODUCTION:

The coexistence of common and rare conditions in a single person may represent a diagnostic challenge. We herein report the case of a young gentleman diagnosed with an acute HIV infection who had a history of myalgias and exercise intolerance and experienced elevated creatinine and phosphokinase enzyme levels.

CLINICAL PRESENTATION:

A 24-year-old gentleman was diagnosed with an acute HIV in May 2023 (HIV-RNA > 10.000.000 copies/ml, CD4+ count 417 cell/L) and started same-day combinarion antiretroviral therapy, cART, with darunavir/cobicistat/tenofovir alafenamide/emtricitabine+dolutegravir), switching to dolutegravir/lamivudine once undetectable, 6 weeks after. After 5 months, he was hospitalized with fever, headache, and acute renal failure (creatinine 500 umol/L). Later, CPK peaked at >22,000 mg/dl. He denied chemsex/drug use and had recently started exercising on a regular basis. HIV-RNA was undetectable, cerebrospinal fluid (CSF) examination was unremarkable. cART was temporarily stopped with the normalization of labs. After 20 days, cART was restarted, as well as physical activity, with relapse of the symptoms requiring rehospitalization. Workups for autoimmune and infectious causes were negative. Suspecting drug-related myositis (data on myopathies under integrase inhibitors have been reported), muscle MRI, muscle biopsy, genetic analyses, hair analysis were performed. He tested positive for cocaine and amphetamines. Muscle biopsy showed type 1 fiber atrophy while muscle magnetic resonance imaging was unremarkable. In January 2025, genetic testing came back confirming type VII glycogenosis.

DISCUSSION:

This case highlights the diagnostic complexity of rare metabolic disorders, especially when coexisting with acute HIV, continuous medication use and drug exposure. It allows us to highlight the importance of considering rare metabolic disorders as differential diagnoses, as they can mimic systemic illnesses or drug-related effects.

31 Dec 2025·HIV Research & Clinical Practice

Evaluation of the effect of 48 weeks of BIC/F/TAF and DRV/c/F/TAF on platelet function in the context of rapid ART start

Article

Author: Boffito, Marta ; Henderson, Merle ; Whitlock, Gary ; Khawaja, Akif A. ; Taylor, Graham P. ; Fidler, Sarah ; Soler-Carracedo, Alfredo ; Emerson, Michael

INTRODUCTION:

The BIC-T&T study aimed to determine the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/c/F/TAF) at suppressing viral load in a two-arm, open-label, multi-centre, randomised trial under a UK test-and-treat setting. This sub-study aimed to evaluate potential off-target cardiovascular impact by examining ex vivo platelet function.

METHODS:

Platelets were isolated by centrifugation of citrated blood from participants attending Chelsea and Westminster Hospital or St Mary's Hospital at Week 48 following enrolment. Platelet activation was assessed by real-time flow cytometry to examine integrin activation and granule release and platelet aggregation was evaluated by light transmission aggregometry. Statistical significance was determined by 2-way ANOVA with a Šidák's multiple comparisons post-test.

RESULTS:

An analysis of 21 participants was performed at Week 48 (96% male and 48% white; mean (range) age was 37 (23-78) years). No difference between arms was observed in ADP-, collagen- or thrombin receptor activator for peptide (TRAP)-6-evoked platelet α_IIbβ₃ integrin activation, granule release or platelet aggregation in response to any of the agonists tested. Despite differences in the demographics between treatment arms, the presence of an unboosted integrase inhibitor or boosted protease inhibitor in a test-and-treat setting did not impact platelet function.

CONCLUSIONS:

Our study provides no evidence of differences in downstream platelet responses between participants taking BIC/F/TAF compared to DRV/c/F/TAF following 48 wk of treatment. Further data are required to explore whether there are biologically significant off-target effects, including effects on platelets and other components of the cardiovascular system between these two test-and-treat regimens.

CLINICAL TRIAL NUMBER:

NCT04653194.

221

News (Medical) associated with Tenofovir Alafenamide Fumarate

28 Nov 2025

·www.pharmaceutical-technology.com

Over half of European HIV patients diagnosed late, ECDC report finds

The ECDC’s 2025 HIV Surveillance Report has found that 54% of patients diagnosed with HIV in 2024 were diagnosed too late to receive fully effective treatment. Image credit: Corona Borealis Studio via Shutterstock.com. A European 2025 HIV/AIDS surveillance report has revealed that countries within the continent are currently failing to test and treat HIV early. The annual report, published by the European Centre for Disease Prevention and Control (ECDC), was released on 27 November 2025 but looks at 2024 data. While the report identified a small downturn in HIV cases between 2023 and 2024, testing gaps were still highly prevalent. This is evidenced by the fact that 54% of patients with HIV across the World Health Organization (WHO) European region in 2024 were unable to receive optimal treatment due to late diagnosis. This is notable as patients with a delayed HIV diagnosis are less likely to gain the full benefits of antiretroviral (ART) therapies. Currently, ART therapies are the mainstay treatment option for patients diagnosed with HIV, as they can suppress viral load and prevent transmission. According to the annual report, 105,922 HIV diagnoses were made across the WHO European region in 2024, which includes 53 countries. Of those receiving late diagnoses, the highest proportion were heterosexual patients – especially men – as well as people that inject drugs. As current testing initiatives across Europe are currently failing to diagnose a majority of patients early, the ECDC noted that the 2030 goal of ending AIDS as a public health threat could be in jeopardy. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence To ensure this goal is achieved, the ECDC and the WHO’s European division are calling for the scale-up and routinisation of HIV testing across the continent, with a key focus on self-testing and community-based options. According to Hans Henri P. Kluge, WHO regional director for Europe, tackling the silent HIV crisis will involve “removing the deadly barriers of stigma and discrimination” that currently discourage individuals from seeking out a HIV test. Meanwhile, Pamela Rendi-Wagner, director of the ECDC, stressed the importance of innovating testing strategies, while “ensuring rapid linkage to care” to improve patient outcomes. A major hit to global HIV treatment efforts came this year came when President Donald Trump cut a large amount of funding for foreign aid. This impacted HIV, malaria and tuberculosis treatment services in low-income countries supported by the United States Agency for International Development (USAID). Trump also trimmed financial support for the president’s Emergency Plan for AIDS Relief (PEPFAR). The plan has become a major pillar in fighting the global HIV/AIDS response, providing testing services, antiretroviral treatment and education programmes. HIV treatments advance Currently, HIV remains a major threat to public health, with the WHO estimating that 40.8 million were living with the disease globally at the end of 2024. However, there are a wide range of effective ART options available to patients, meaning that those with access to medications have a similar life expectancy to an individual living without HIV. The most widely prescribed ART is currently Gilead’s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), which had a strong financial showing in Q2 2025, with sales jumping 9% to $3.5bn. While the drug’s patent is up for expiry as early as October 2027, GlobalData analysts predict that no other HIV therapy is likely to surpass Biktarvy in terms of commercial success. Alongside Biktarvy, Gilead has found a new key asset in Yeztugo (lenacapavir), which the US Food and Drug Administration (FDA) approved as a biannual pre-exposure prophylaxis (PrEP) for patients at risk of HIV in June 2025. While this treatment is only suitable as a preventive measure, GlobalData analysts note that the therapy is set to revolutionise the HIV landscape. Now, some companies are looking to cure HIV completely. This includes American Gene Technologies, which is currently looking to take its potentially curative cell therapy, AGT103-T, to additional trials after a Phase I study yielded promising results . The International AIDS Vaccine Initiative is also working towards a preventive vaccine for HIV, which has seen an adenovirus vaccine enter Phase I clinical trials in Africa. Currently, the jab is being tested in both HIV-positive and HIV-negative individuals. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

VaccinePhase 1Clinical ResultDrug Approval

19 Nov 2025

·endpoints.news

Merck says once-daily HIV drug combo succeeds in another Phase 3

Merck secured another win on Wednesday in its plan to bolster its HIV portfolio. The pharma giant said its two-drug combination was non-inferior to a three-drug package in a Phase 3 trial in adults with HIV-1 who were not previously on antiretroviral treatment. Merck said the study of the single-tablet combination of doravirine and islatravir met the primary efficacy hypothesis at week 48. The safety of DOR/ISL was also “comparable” to the three-drug combination of Gilead’s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, or BIC/FTC/TAF). Both are once-daily regimens. DOR/ISL is already under FDA review for a different patient population : people with HIV who are already on an antiretroviral regimen. The regulatory body is slated to decide whether to approve the treatment in that population by April 28 . Merck hopes DOR/ISL will become part of a broader HIV portfolio that could be a $5 billion business . Its existing medicines in the space made $412 million in revenue in the first half of this year, but it’s studying additional combinations and a once-monthly oral PrEP that just entered Phase 3. Merck has been involved in HIV science since the early days of the epidemic, and brought the protease inhibitor Crixivan to market in 1996. Multiple HIV treatment options now exist, and companies like Gilead and GSK’s ViiV make long-acting HIV medicines, but for different patient populations. Merck’s existing HIV work is a small piece of the pharma’s efforts to pad the revenue gap that will come from Keytruda’s patent cliff. Merck has spent more than $19 billion this year on acquisitions, namely for respiratory biotech Verona Pharma and influenza antiviral developer Cidara Therapeutics . The new Phase 3 data will be presented at a future medical conference. Merck said it plans to use the data in applications to health regulators. With the non-inferiority results, Merck hopes to go up against Biktarvy, which brought in $3.7 billion in sales for Gilead in the third quarter of this year. “These data support the potential for this regimen to be a meaningful treatment option for virally suppressed people living with HIV who are looking to switch to a new regimen or people who have not previously been on antiretroviral therapy to start treatment,” Merck Research Laboratories chief medical officer Eliav Barr said in a press release. Merck chief marketing officer Chirfi Guindo said on an investor call in July that the company believes DOR/ISL will be “the preferred switch option for many individuals.” Guindo said the drug combination provides “robust viral control” and a “high barrier to resistance.” Doravirine is an approved HIV medicine known as Pifeltro and part of an HIV pill marketed as Delstrigo. Islatravir, meanwhile, is in multiple clinical trials assessing whether it can be a once-daily or weekly treatment for HIV when paired up with other medicines. The drug is in Phase 3 with Gilead’s lenacapavir as a potential once-weekly oral treatment. Islatravir is also in a Phase 2b in combination with Merck’s ulonivirine, an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). That pairing is “back on track,” Luisa Stamm, Merck’s associate VP and section head for HIV, said in an interview with Endpoints in July. The drug combo had a safety signal for a prior Phase 2, but Merck is now looking at a lower dosing schedule to assuage concerns.

Phase 3Phase 2AcquisitionClinical Result

19 Nov 2025

·firstwordpharma.com

Merck & Co.'s HIV tablet matches Biktarvy in treatment-naïve patients

The race for a simplified HIV antiretroviral regimen is heating up. Days after Gilead shared data on its experimental two-drug, single-tablet treatment, Merck & Co. has countered with late-stage findings for its own drug duo — though this batch of pivotal results is in treatment-naïve patients. The current standard-of-care HIV viral suppressor is Gilead's Biktarvy, an oral, once-daily tablet that comprises integrase strand transfer inhibitor (INSTI) bictegravir plus emtricitabine and tenofovir alafenamidei. The drug is Gilead's best-seller, bringing in $3.7 billion in revenue for the third quarter (see – Vital Signs: Gilead's fastest growing drugs).Last week, Gilead revealed data from the Phase III ARTISTRY-1 study evaluating a single-tablet combination of bictegravir plus lenacapavir, a long-acting HIV-1 capsid inhibitor marketed as Sunlenca for multidrug-resistant HIV and as Yeztugo for pre-exposure prophylaxis. In the 689 participants — all of whom were virologically suppressed, but were taking anywhere from two to 11 pills daily — bictegravir/lenacapavir was statistically non-inferior to multi-tablet regimens at the 48-week mark. Integrase inhibitor not needed?Merck is comparing its single-tablet, two-drug combo of doravirine/islatravir against Biktarvy in a Phase III study. Unlike Biktarvy or Gilead's experimental duo, Merck's pill does not include an INSTI; islatravir is a nucleoside reverse transcriptase translocation inhibitor designed to block HIV-1 replication via chain termination and induction of structural changes.The MK-8591A-053 trial enrolled 537 patients with HIV-1 infection who've never received an antiretroviral. After 48 weeks, Merck's tablet met its primary endpoint, demonstrating non-inferiority to Biktarvy as measured by the percentage of participants with HIV-1 RNA levels <50 copies/mL. The pharma added that the safety profile of doravirine/islatravir was comparable to Gilead's drug. Doravirine/islatravir "is the first two-drug regimen without an integrase inhibitor showing non-inferior efficacy and safety when compared to the three-drug INSTI-based regimen [Biktarvy] in this population," said Eliav Barr, head of global clinical development and the chief medical officer at Merck Research Laboratories. "These data support the potential for this regimen to be a meaningful treatment option for virally suppressed people living with HIV who are looking to switch to a new regimen or people who have not previously been on antiretroviral therapy to start treatment."Merck's two-drug combo is already under review at the FDA for adults with HIV who are virologically suppressed on antiretroviral therapy. With a PDUFA date of April 28, 2026, it has a head-start on Gilead's bictegravir/lenacapavir in the pre-treated population, where the biopharma is still waiting for results to read out from a second Phase III trial, ARTISTRY-2.Detailed results of doravirine/islatravir in treatment-naïve patients will be presented at a future scientific meeting, and submitted to global regulators.

Phase 3Clinical Result

100 Deals associated with Tenofovir Alafenamide Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D10605	Tenofovir Alafenamide Fumarate	J05AF13	DB09299

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Virus Diseases	China	Gilead Sciences Ireland UC	09 May 2019
Hepatitis B, Chronic	United States	Gilead Sciences, Inc.	10 Nov 2016
Liver Diseases	United States	Gilead Sciences, Inc.	10 Nov 2016
HIV Infections	Canada	Gilead Sciences Canada, Inc.	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fatigue	Phase 2	United States	Gilead Sciences, Inc.	15 Sep 2022
Multiple Sclerosis, Relapsing-Remitting	Phase 2	United States	Gilead Sciences, Inc.	15 Sep 2022
Acquired Immunodeficiency Syndrome	Phase 2	United States	Gilead Sciences, Inc.	01 Apr 2019
Mitochondrial Cytopathy	Phase 2	United States	Gilead Sciences, Inc.	01 Apr 2019
Chronic Kidney Diseases	Phase 2	New Zealand	Gilead Sciences, Inc.	16 Sep 2016
Hepatitis B	Phase 1	United States	Gilead Sciences, Inc.	22 Dec 2014
Hepatitis B	Phase 1	Germany	Gilead Sciences, Inc.	22 Dec 2014
Hepatitis B	Phase 1	New Zealand	Gilead Sciences, Inc.	22 Dec 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05140954 (CTgov)	Phase 2/3	HIV Infections	54	co-formulated 25mg TAF/ 200mg FTC (Poor Adherence)	inkmxiilaq = cchtpokezv dhxflzacxt (ivqtabvtxy, sfnrdxdpoa - mrztnxqjgq) View more	-	27 Oct 2025
				co-formulated 25mg TAF/ 200mg FTC (Moderate Adherence)	inkmxiilaq = hqaubailcr dhxflzacxt (ivqtabvtxy, mppqtynviy - obbppeefoo) View more
NCT02862548 (Pubmed \| Am J Transplant)	Phase 2	Chronic Kidney Diseases	51	Tenofovir alafenamide	oiryshjcpk(igjtpowcke) = ezutdfukug pvxtodtrjv (cspvdstodr )	Positive	01 Sep 2025
				Tenofovir disoproxil fumarate	oiryshjcpk(igjtpowcke) = wnzqsvntoy pvxtodtrjv (cspvdstodr )
NCT03753074 (ATTENTION, Pubmed \| Lancet Gastroenterol Hepatol)	Phase 4	Hepatitis B, Chronic	734	Tenofovir alafenamide 25 mg daily	nodjdwsegn(ihwmieaokc) = skslridwyp oqymmpumvv (vjsjwajzoy )	Positive	01 Apr 2025
				tenofovir alafenamide (Observation)	nodjdwsegn(ihwmieaokc) = sgqnhwziaj oqymmpumvv (vjsjwajzoy )
NEWS Manual	Phase 3	Hepatitis B, Chronic	334	TAF (25 mg) (Chinese)	wssjuajnec(hwmpbrfhag) = hoysloellt wevpzpfepp (kemujkuwom ) View more	Positive	27 Mar 2025
				TDF (300 mg) (Chinese)	wssjuajnec(hwmpbrfhag) = knckmfutiw wevpzpfepp (kemujkuwom ) View more
NEWS Manual	Not Applicable	Hepatitis B \| Hepatitis C	105	TAF + 索磷布韦维帕他韦（SOF/VEL） (非肝硬化)	btiimqvksl(lkmauktjhl) = lxopqiqhna souavowoys (thuvydzghe ) View more	Positive	27 Mar 2025
				TAF + 索磷布韦维帕他韦（SOF/VEL） (代偿期肝硬化)	btiimqvksl(lkmauktjhl) = kimcixfyrb souavowoys (thuvydzghe ) View more
NCT01940471 \| NCT01940341 (two phase 3 studies, Pubmed \| Aliment Pharmacol Ther) Manual	Phase 3	Hepatitis B, Chronic	1,298	tenofovir alafenamide (TAF8y)5 mg/day	nzcgcruooj(jzjifdyqbj) = remained stable in patients receiving double-blind/OL TAF, with only small declines at year 8. Decreases in BMD observed during double-blind TDF improved after switching to OL TAF iqaapuuhny (wuxgijgndu )	Positive	01 Dec 2024
				Tenofovir disoproxil fumarate (TDF2y)00tenofovir alafenamide (TAF6y
NCT03920618 (Pubmed \| Liver Res)	Not Applicable	Acute-On-Chronic Liver Failure	199	Tenofovir alafenamide (TAF)	labhubqrdk(nzzpxrvqvs) = pxdcspiiss wzdjtubhfd (mxikorajtb ) View more	Positive	01 Dec 2024
				Tenofovir disoproxil fumarate (TDF)	labhubqrdk(nzzpxrvqvs) = gywkybgfgi wzdjtubhfd (mxikorajtb ) View more
NEWS Manual	Not Applicable	Hepatitis B, Chronic	130	TMF	ruzfmktayr(jqrslulaly) = sobgguwtjb kukxqmzljp (kwdqojgnkh ) View more	Positive	18 Nov 2024
				TAF	ruzfmktayr(jqrslulaly) = niczljcjcu kukxqmzljp (kwdqojgnkh ) View more
NCT04850950 (Pubmed \| Am J Gastroenterol)	Phase 4	Hepatitis B HBV DNA	239	Expected Eight-Week Prenatal Tenofovir Alafenamide Prophylaxis	gfiicvhhga(qsccjapzlx) = ydzrbkulij grnsnsizym (cfwvnilhkn, 4.5% - 11.1) View more	Positive	09 Oct 2024
				Expected Twelve-Week Perinatal Tenofovir Alafenamide Prophylaxis	hhkkyxrdhx(pswnaozujf) = exgfydofwx zseeosxgrz (mcgmxayztb )
NCT04937881 (PrEP-PP PK, CTgov)	Phase 3	HIV Infections	39	Tenofovir Alafenamide (TAF Arm)	fwddfxuhgl(pimftodqwh) = qqjpuzgfdc gdjvnnirbh (fjwqdhross, jzyswxqdyf - bpfykdipyf) View more	-	03 Sep 2024
				Tenofovir Disoproxil Fumarate (TDF Arm)	fwddfxuhgl(pimftodqwh) = lcuhcicrpn gdjvnnirbh (fjwqdhross, ewoztnalox - onuehoekgu) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis